Trial intelligence / Profile preview

Indisulam plus capecitabine versus capecitabine alone in metastatic breast cancer after anthracycline and taxane therapy

2004-000774-31Phase 2Completed

Sponsor
Eisai Co., Ltd.
Start
Feb 2005
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, randomised, open-label trial in breast cancer comparing Indisulam + capecitabine with Capecitabine monotherapy (2 arms). Primary endpoint: Time to progression. Started Feb 2005; status: completed.

02

Drugs

indisulamcapecitabine
03

Conditions

breast cancer

Beyond the preview

Go deeper on 2004-000774-31.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2004-000774-31.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call